Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 2
1985 1
1986 1
1987 2
1988 2
1989 2
1990 5
1991 6
1992 8
1993 3
1994 13
1995 10
1996 21
1997 13
1998 13
1999 17
2000 19
2001 14
2002 19
2003 28
2004 31
2005 41
2006 47
2007 55
2008 68
2009 108
2010 128
2011 153
2012 157
2013 211
2014 229
2015 285
2016 297
2017 363
2018 431
2019 451
2020 630
2021 645
2022 849
2023 827
2024 869
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,350 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: xiong j. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy.
Franken A, Bila M, Mechels A, Kint S, Van Dessel J, Pomella V, Vanuytven S, Philips G, Bricard O, Xiong J, Boeckx B, Hatse S, Van Brussel T, Schepers R, Van Aerde C, Geurs S, Vandecaveye V, Hauben E, Vander Poorten V, Verbandt S, Vandereyken K, Qian J, Tejpar S, Voet T, Clement PM, Lambrechts D. Franken A, et al. Among authors: xiong j. Immunity. 2024 Mar 12;57(3):541-558.e7. doi: 10.1016/j.immuni.2024.02.007. Epub 2024 Mar 4. Immunity. 2024. PMID: 38442708
Low glucose metabolite 3-phosphoglycerate switches PHGDH from serine synthesis to p53 activation to control cell fate.
Wu YQ, Zhang CS, Xiong J, Cai DQ, Wang CZ, Wang Y, Liu YH, Wang Y, Li Y, Wu J, Wu J, Lan B, Wang X, Chen S, Cao X, Wei X, Hu HH, Guo H, Yu Y, Ghafoor A, Xie C, Wu Y, Xu Z, Zhang C, Zhu M, Huang X, Sun X, Lin SY, Piao HL, Zhou J, Lin SC. Wu YQ, et al. Among authors: xiong j. Cell Res. 2023 Nov;33(11):835-850. doi: 10.1038/s41422-023-00874-4. Epub 2023 Sep 19. Cell Res. 2023. PMID: 37726403 Free PMC article.
Magnaporthe oryzae effector MoSPAB1 directly activates rice Bsr-d1 expression to facilitate pathogenesis.
Zhu Z, Xiong J, Shi H, Liu Y, Yin J, He K, Zhou T, Xu L, Zhu X, Lu X, Tang Y, Song L, Hou Q, Xiong Q, Wang L, Ye D, Qi T, Zou L, Li G, Sun C, Wu Z, Li P, Liu J, Bi Y, Yang Y, Jiang C, Fan J, Gong G, He M, Wang J, Chen X, Li W. Zhu Z, et al. Among authors: xiong j. Nat Commun. 2023 Dec 18;14(1):8399. doi: 10.1038/s41467-023-44197-9. Nat Commun. 2023. PMID: 38110425 Free PMC article.
6,350 results